BioVie can sell up to $6,464,341 ($6.46 million) of Class A common stock through A.G.P. under an at-the-market agreement, with proceeds intended for general corporate purposes. Investors face potential dilution, while the final amount raised, commissions and net proceeds remain dependent on sales because the offering has no minimum requirement.
Key Highlights
- BioVie may sell up to $6,464,341 of Class A common stock through A.G.
- The offering has no minimum amount required as a condition to close.
- BioVie intends to use any net proceeds for general corporate purposes.
BIOVIE INC. (NASDAQ: BIVI) can sell up to $6,464,341 ($6.46 million) of Class A common stock through A.G.P. Under an at-the-market sales agreement.
A.G.P. To Handle At-the-Market Sales
A.G.P. May act as BioVie’s sales agent or principal for transactions conducted from time to time. The shares carry a Par Value of $0.0001 per share, and the last reported sales price on September 8 was $2.07 per share. It excludes 2,785,363 shares issuable through options, 7,293,498 shares issuable through warrants and 300 shares tied to restricted stock units.
Dilution Disclosure
The filing reports an as-adjusted net tangible Book Value of $11.4 million, or $1.34 per share. The prospectus says a purchaser’s interest may be diluted by the difference between the public offering price and the adjusted net tangible book value per share.
FAQs
Q: How much common stock can BioVie sell in its ATM offering?
A: BioVie may sell up to $6,464,341 of Class A common stock through A.G.P. Under the at-the-market arrangement. The agreement does not require a minimum offering amount.
Q: What could dilute BioVie shareholders under the offering?
A: BioVie identifies potential dilution from the offering price relative to adjusted net tangible book value per share. Outstanding options, warrants and restricted stock units are also excluded from the stated share count.
Q: How does BioVie plan to use the offering proceeds?
A: BioVie intends to apply net proceeds to general corporate purposes. Management retains discretion over allocation, and pending those uses, BioVie plans to invest the net proceeds in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.